Aigen Investment Management LP grew its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 238.3% in the third quarter, HoldingsChannel reports. The fund owned 32,664 shares of the life sciences company's stock after buying an additional 23,009 shares during the quarter. Aigen Investment Management LP's holdings in Integra LifeSciences were worth $1,384,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Wipfli Financial Advisors LLC purchased a new stake in Integra LifeSciences during the third quarter valued at about $29,000. First Horizon Advisors Inc. purchased a new stake in Integra LifeSciences during the 2nd quarter worth $54,000. Aubrey Capital Management Ltd purchased a new position in Integra LifeSciences in the second quarter valued at about $76,000. Covestor Ltd lifted its stake in shares of Integra LifeSciences by 63.0% during the first quarter. Covestor Ltd now owns 1,558 shares of the life sciences company's stock worth $100,000 after purchasing an additional 602 shares in the last quarter. Finally, Huntington National Bank grew its stake in shares of Integra LifeSciences by 25.9% in the third quarter. Huntington National Bank now owns 2,826 shares of the life sciences company's stock valued at $120,000 after buying an additional 581 shares in the last quarter. 87.60% of the stock is currently owned by hedge funds and other institutional investors.
Get Integra LifeSciences alerts:Integra LifeSciences Trading Down 2.6 %
NASDAQ IART opened at $58.04 on Tuesday. Integra LifeSciences Holdings Co. has a 12 month low of $40.67 and a 12 month high of $68.29. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.93 and a quick ratio of 2.91. The company has a market capitalization of $4.85 billion, a price-to-earnings ratio of 28.17, a price-to-earnings-growth ratio of 1.68 and a beta of 1.12. The company's fifty day moving average price is $56.69 and its two-hundred day moving average price is $51.99.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on IART. Morgan Stanley upped their price target on Integra LifeSciences from $50.00 to $59.00 and gave the stock an "equal weight" rating in a report on Friday, January 6th. Jefferies Financial Group assumed coverage on shares of Integra LifeSciences in a report on Tuesday, October 11th. They set a "hold" rating and a $48.00 price target for the company. JMP Securities cut their price objective on shares of Integra LifeSciences from $85.00 to $75.00 and set a "market outperform" rating on the stock in a report on Thursday, October 27th. TheStreet upgraded Integra LifeSciences from a "c+" rating to a "b-" rating in a research note on Tuesday, December 27th. Finally, Truist Financial lifted their target price on Integra LifeSciences from $52.00 to $58.00 and gave the stock a "hold" rating in a research report on Tuesday, December 20th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $58.33.Integra LifeSciences Company Profile
(Get Rating)
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.
See Also
- Get a free copy of the StockNews.com research report on Integra LifeSciences (IART)
- Why Is Wall Street Loving Amazon So Much?
- Want to Invest in ChatGPT? Then Buy Microsoft Stock
- Anhui Conch: Opportunity With Cement Solid Cash Flows
- Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
- Is Biotech Immunocore About To Make A 25% Price Move?
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating).
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.